Tolerance of high-dose coenzyme Q10 in ALS

Study Purpose:

An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

Study Status:

Not recruiting

Disease:

Amyotrophic Lateral Sclerosis (ALS) , Familial ALS , Sporadic ALS

Study Type:

Interventional

Type of Intervention:

Drug Trial

Intervention Name:

Placebo:

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

Merit Cudkowicz, Massachusetts General Hospital

Clinicaltrials.gov ID:

Neals Affiliated?

Yes

Coordinating Center Contact Information